^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    IDH wild-type

    i
    Other names: HEL-216, HEL-S-26, Epididymis Luminal Protein 216, Isocitrate Dehydrogenase 1 (NADP+), Epididymis Secretory Protein Li 26, IDH1, Isocitrate Dehydrogenase (NADP(+)) 1, Isocitrate Dehydrogenase 1 (NADP+), Soluble, IDH2, Isocitrate Dehydrogenase (NADP(+)) 2, Isocitrate Dehydrogenase (NADP(+)) 2, Mitochondrial, Isocitrate Dehydrogenase 2 (NADP+), Mitochondrial, Isocitrate Dehydrogenase [NADP], Mitochondrial, Oxalosuccinate Decarboxylase, NADP(+)-Specific ICDH, ICD-M, IDH, IDP, MNADP-IDH, D2HGA2, IDHM, IDPM
    Entrez ID:
    3417; 3418
    Related biomarkers:
    Expression
    Mutation
    Others
    1d
    Temporally-Modulated Pulsed Radiation Therapy Versus Standard Radiation Therapy for the Treatment of Newly Diagnosed, IDH Wildtype, MGMT-Unmethylated Glioblastoma (clinicaltrials.gov)
    P3, N=398, Not yet recruiting, NRG Oncology
    New P3 trial
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • MGMT (6-O-methylguanine-DNA methyltransferase)
    |
    MGMT promoter methylation • IDH wild-type • IDH1 R132
    |
    temozolomide
    2d
    GLIOTARG: Comprehensive Analysis of Chemotherapy and Targeted Therapy Outcomes in Recurrent Malignant Gliomas (clinicaltrials.gov)
    P=N/A, N=1000, Active, not recruiting, Blokhin's Russian Cancer Research Center
    New trial
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2)
    |
    IDH wild-type
    |
    Avastin (bevacizumab) • carboplatin • irinotecan
    2d
    Surgical Pembro +/- Olaparib w TMZ for rGBM (clinicaltrials.gov)
    P2, N=78, Recruiting, L. Nicolas Gonzalez Castro, MD, PhD | Trial completion date: Nov 2026 --> Mar 2027 | Trial primary completion date: Feb 2026 --> Aug 2026
    Trial completion date • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor) • TERT (Telomerase Reverse Transcriptase)
    |
    EGFR mutation • EGFR amplification • IDH wild-type
    |
    Keytruda (pembrolizumab) • Lynparza (olaparib) • temozolomide
    2d
    Effect of stRess and exeRcize on the Outcome After Chemo-Radiation (clinicaltrials.gov)
    P=N/A, N=42, Completed, Maastricht Radiation Oncology | Recruiting --> Completed | Trial completion date: Dec 2025 --> Mar 2026 | Trial primary completion date: Dec 2025 --> Mar 2026
    Trial completion • Trial completion date • Trial primary completion date
    |
    IDH wild-type
    2d
    Spatial Transcriptomics Characterisation of Radionecrotic Changes in Glioblastoma Patients. (PubMed, Neuro Oncol)
    This study delineates a complex spatial architecture of brain tissue with post-treatment changes and its discrepancies from progressive GB, thus facilitating future research into novel treatment strategies.
    Journal
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR expression • IDH wild-type
    |
    temozolomide
    2d
    CAN-201 NDG: Azeliragon and Chemoradiotherapy in Newly Diagnosed Glioblastoma (clinicaltrials.gov)
    P1/2, N=18, Recruiting, Cantex Pharmaceuticals | Not yet recruiting --> Recruiting
    Enrollment open
    |
    S100A9 (S100 Calcium Binding Protein A9)
    |
    IDH wild-type
    |
    temozolomide • azeliragon (TTP488)
    2d
    GlitIpNi: A phase IB clinical trial on neoadjuvant and intraoperative intracranial nadministration of triple immune checkpoint blockade plus myeloid dendritic ncells in patients with recurrent high-grade glioma (clinicaltrials.gov)
    P1, N=110, Active, not recruiting, Universitair Ziekenhuis Brussel | Phase classification: P1/2 --> P1
    Phase classification • Checkpoint inhibition
    |
    IDH wild-type
    |
    Yervoy (ipilimumab) • Opdualag (nivolumab/relatlimab-rmbw)
    2d
    Machine Learning-Based Preoperative Predicting TERT Promoter Mutation and EGFR Gene Amplification Phenotype in IDH Wild-Type Glioblastoma Using Advanced MR Habitat Imaging. (PubMed, AJNR Am J Neuroradiol)
    The tumor habitat imaging model based on advanced MRI was useful for accurately predicting TERT promoter mutation and EGFR amplification status in IDH wild-type glioblastoma.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • TERT (Telomerase Reverse Transcriptase)
    |
    EGFR mutation • EGFR amplification • IDH wild-type
    3d
    A Study of the Treatment of Recurrent Malignant Glioma With rQNestin34.5v.2 (clinicaltrials.gov)
    P1, N=62, Active, not recruiting, Dana-Farber Cancer Institute | Recruiting --> Active, not recruiting | Trial completion date: Jan 2027 --> Jan 2028 | Trial primary completion date: Jan 2026 --> Jan 2027
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1)
    |
    IDH1 mutation • IDH wild-type • IDH1 R132
    |
    cyclophosphamide • linoserpaturev (CAN-3110)
    4d
    A Study Testing the Effect of Immunotherapy (Ipilimumab and Nivolumab) in Patients With Recurrent Glioma With Elevated Mutational Burden (clinicaltrials.gov)
    P2, N=37, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: May 2026 --> Dec 2026 | Trial primary completion date: May 2026 --> Dec 2026
    Trial completion date • Trial primary completion date • Checkpoint inhibition • Tumor mutational burden • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • TP53 (Tumor protein P53) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • TERT (Telomerase Reverse Transcriptase) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B) • ATRX (ATRX Chromatin Remodeler)
    |
    TP53 mutation • EGFR mutation • EGFR amplification • CDKN2A deletion • IDH wild-type
    |
    FoundationOne® CDx
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • ABP 206 (nivolumab biosimilar)
    7d
    Erlotinib Induces Cell Death by Blocking NIX-mediated Mitophagy Through Lysosomal Swelling in IDH1-mutant Cholangiocarcinoma. (PubMed, Anticancer Res)
    The CCA cell line carrying an IDH mutation utilized mitophagy as a novel metabolic compensatory mechanism activated through EGFR-specific signaling. Mitophagy acted as a metabolic synthetic lethality partner to the EGFR inhibitor erlotinib. These findings strongly suggest the potential of erlotinib as a therapeutic strategy for patients with IDH1-mutant CCA.
    Journal
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • ANXA5 (Annexin A5)
    |
    IDH1 mutation • IDH wild-type
    |
    erlotinib
    8d
    Extent of Resection and Survival in IDH-Wildtype Glioblastoma: A Dual-Center Retrospective Study. (PubMed, Medicina (Kaunas))
    The absence of MGMT promoter methylation status, lack of volumetric EOR quantification (including non-contrast-enhancing/FLAIR disease), and lack of standardized functional outcome data substantially limited causal inference. Prospective studies integrating molecular stratification, volumetric resection metrics, and functional outcome assessments are warranted.
    Retrospective data • Journal
    |
    MGMT (6-O-methylguanine-DNA methyltransferase)
    |
    MGMT promoter methylation • IDH wild-type